HLA class II histocompatibility antigen DRB1 beta chain (HLA-DRB1)

The HLA class II histocompatibility antigen DRB1 beta chain is a highly polymorphic protein encoded by the HLA-DRB1 gene, forming the beta subunit of the HLA-DR heterodimer. As a central component of the Major Histocompatibility Complex (MHC) class II, it is primarily expressed on professional antigen-presenting cells such as B cells, dendritic cells, and macrophages [2, 4]. Its fundamental biological role is to bind and present exogenous peptide antigens to CD4+ T helper cells, thereby initiating and orchestrating the adaptive immune response [3, 7]. Polymorphisms in HLA-DRB1 are the most significant genetic risk factors for numerous autoimmune conditions, including rheumatoid arthritis, multiple sclerosis, and type 1 diabetes [5, 6]. In rheumatoid arthritis, specific sequences known as the "shared epitope" in the DRB1 chain are associated with increased disease severity and bone destruction [13]. Therapeutic interventions include glatiramer acetate, which competes for the peptide-binding groove, and experimental inhibitors designed to block the presentation of autoreactive peptides [1, 16]. Additionally, HLA-DRB1 status serves as a critical biomarker for predicting disease susceptibility, severity, and patient response to immunotherapies [11, 14].

Other names

HLA-DRB1DRB1MHC class II antigen DRB1HLA-DR1BSS1DRw10Major histocompatibility complex class II DR beta 1

Drugs targeting HLA-DRB1 typically function by binding to the peptide-binding groove to prevent the presentation of pathogenic self-antigens to T cells, or by blocking the interaction between the MHC-peptide complex and the T cell receptor (TCR) and its co-receptor CD4 [1, 16]. Some agents, like glatiramer acetate, act as altered peptide ligands that compete for binding and shift the immune response from a pro-inflammatory Th1/Th17 profile to a regulatory Th2/Treg profile [1, 18].